JP2023532807A - Ｐｓｍａ及びガンマ－デルタｔ細胞受容体に結合する抗体 - Google Patents

Ｐｓｍａ及びガンマ－デルタｔ細胞受容体に結合する抗体 Download PDF

Info

Publication number
JP2023532807A
JP2023532807A JP2023501293A JP2023501293A JP2023532807A JP 2023532807 A JP2023532807 A JP 2023532807A JP 2023501293 A JP2023501293 A JP 2023501293A JP 2023501293 A JP2023501293 A JP 2023501293A JP 2023532807 A JP2023532807 A JP 2023532807A
Authority
JP
Japan
Prior art keywords
seq
multispecific antibody
set forth
antibody
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023501293A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532807A5 (https=
JPWO2022008646A5 (https=
Inventor
ロベルトゥス・コーネリス・ローフェルス
ヨハネス・イェレ・ファン・デル・フリート
リサ・アンネ・キング
パウル・ウィレム・ヘンリ・イダ・パレン
ヴィクトリア・グイマライス・イグレシアス
ダーフィット・ルーチェ・ヒュルシク
ペーテル・アレクサンデル・ヘーラルドス・マリア・マヒエルセン
Original Assignee
ラヴァ・セラピューティクス・エヌ・ヴイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラヴァ・セラピューティクス・エヌ・ヴイ filed Critical ラヴァ・セラピューティクス・エヌ・ヴイ
Publication of JP2023532807A publication Critical patent/JP2023532807A/ja
Publication of JP2023532807A5 publication Critical patent/JP2023532807A5/ja
Publication of JPWO2022008646A5 publication Critical patent/JPWO2022008646A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2023501293A 2020-07-08 2021-07-08 Ｐｓｍａ及びガンマ－デルタｔ細胞受容体に結合する抗体 Pending JP2023532807A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20184800 2020-07-08
EP20184800.9 2020-07-08
PCT/EP2021/068960 WO2022008646A1 (en) 2020-07-08 2021-07-08 Antibodies that bind psma and gamma-delta t cell receptors

Publications (3)

Publication Number Publication Date
JP2023532807A true JP2023532807A (ja) 2023-07-31
JP2023532807A5 JP2023532807A5 (https=) 2024-07-19
JPWO2022008646A5 JPWO2022008646A5 (https=) 2024-07-19

Family

ID=71527722

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023501293A Pending JP2023532807A (ja) 2020-07-08 2021-07-08 Ｐｓｍａ及びガンマ－デルタｔ細胞受容体に結合する抗体

Country Status (11)

Country Link
US (2) US20230272110A1 (https=)
EP (1) EP4178981A1 (https=)
JP (1) JP2023532807A (https=)
KR (1) KR20230042035A (https=)
CN (1) CN116323667A (https=)
AU (1) AU2021305396A1 (https=)
BR (1) BR112023000269A2 (https=)
CA (1) CA3188601A1 (https=)
IL (1) IL299748A (https=)
MX (1) MX2023000448A (https=)
WO (1) WO2022008646A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
EP4292609A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
EP4292610A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
JP2025519645A (ja) * 2022-06-23 2025-06-26 ラヴァ・セラピューティクス・エヌ・ヴイ Ｔ細胞依存性多重特異性化合物のアッセイ
CN121426967A (zh) * 2023-02-10 2026-01-30 阿穆尼克斯制药公司 靶向前列腺特异性膜抗原（psma）的组合物及其制备和使用方法
EP4438624A1 (en) * 2023-03-27 2024-10-02 LAVA Therapeutics N.V. Antibodies that bind nectin-4 and gamma-delta t cell receptors
WO2024200573A1 (en) 2023-03-27 2024-10-03 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use
WO2025012118A2 (en) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513521A (ja) * 2014-04-10 2017-06-01 シュティヒティング・フェーウーエムセー ヒトＶγ９Ｖδ２ Ｔ細胞受容体と結合する免疫グロブリン
WO2018098354A1 (en) * 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
JP2018188437A (ja) * 2017-05-05 2018-11-29 アムジエン・インコーポレーテツド 改善された貯蔵及び投与のための、二重特異性抗体構築物を含む医薬組成物
WO2019055841A1 (en) * 2017-09-14 2019-03-21 Denali Therapeutics Inc. ANTI-TREM2 ANTIBODIES AND METHODS OF USE
JP2019535763A (ja) * 2016-11-23 2019-12-12 ハープーン セラピューティクス，インク． 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
WO2019246514A1 (en) * 2018-06-21 2019-12-26 Regeneron Pharmaceuticals, Inc. Bispecific anti-psma x anti-cd28 antibodies and uses thereof
WO2020060406A1 (en) * 2018-09-19 2020-03-26 Lava Therapeutics B.V. Novel bispecific antibodies for use in the treatment of hematological malignancies
US20200190193A1 (en) * 2018-10-11 2020-06-18 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698880B1 (fr) 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
US6737398B1 (en) 1999-09-30 2004-05-18 National Jewish Medical And Research Center Modulation of γδ T cells to regulate airway hyperresponsiveness
WO2001022816A1 (en) 1999-09-30 2001-04-05 National Jewish Medical And Research Center MODULATION OF ηδ T CELLS TO REGULATE AIRWAY HYPERRESPONSIVENESS
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
WO2003034903A2 (en) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
KR101033196B1 (ko) 2002-02-14 2011-05-09 이뮤노메딕스, 인코오포레이티드 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
EP1587838B1 (en) 2003-01-10 2015-04-15 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation
EP1587837B1 (en) 2003-01-28 2012-06-13 Proscan RX Pharma Inc. Epitope sequences for prostate cancer diagnosis and treatment
WO2005046711A2 (en) 2003-11-07 2005-05-26 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Stimulation or inhibition of gamma delta t-cells to promote or inhibit bone healing
JP5139800B2 (ja) 2004-06-03 2013-02-06 ノビミューン エスアー 抗ｃｄ３抗体およびその使用方法
EP1778836B1 (en) 2004-08-19 2010-08-04 University College Cardiff Consultants Limited Preparation of antigen-presenting human gamma delta t cells and use in immunotherapy
BRPI0607796A2 (pt) 2005-02-18 2009-06-13 Medarex Inc composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica
NZ556661A (en) 2005-02-18 2010-10-29 Medarex Inc Human monoclonal antibodies to prostate specific membrance antigen (PSMA)
EP1726650A1 (en) 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
US8338173B2 (en) 2005-08-11 2012-12-25 University College Cardiff Consultants Limited Preparation of antigen-presenting human γδ T cells and use in immunotherapy
BRPI0617546A2 (pt) 2005-09-26 2011-07-26 Medarex Inc conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
EP1878440A1 (en) 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds
WO2009046294A2 (en) 2007-10-03 2009-04-09 Cornell University Treatment of proliferative disorders using antibodies to psma
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
ITTO20080313A1 (it) 2008-04-22 2009-10-23 Marco Colombatti Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
WO2010111625A1 (en) 2009-03-27 2010-09-30 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
US8629247B2 (en) 2009-04-14 2014-01-14 Proscan Rx Pharma Inc. Antibodies against prostate specific membrane antigen
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
PL2606064T3 (pl) 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
UA118950C2 (uk) 2011-04-22 2019-04-10 Аптево Рісьорч Енд Девелопмент Ллс Поліпептид, який зв'язує специфічний мембранний антиген простати та комплекс т-клітинного рецептора
AU2013201422B2 (en) 2012-01-23 2015-04-09 Ablynx Nv Sequences directed against hepatocyte growth factor (HFG) and polypeptides comprising the same for the treatment of cancers and/or tumors
MX361875B (es) 2012-03-14 2018-12-18 Regeneron Pharma Moléculas de unión de antígeno multiespecifícas y usos de las mismas.
EP2831109B1 (en) 2012-03-28 2017-12-06 Gadeta B.V. Combinatorial gamma 9 delta 2 t cell receptor chain exchange
SI2838917T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
US9745381B2 (en) 2012-05-18 2017-08-29 Scott & White Healthcare (Swh) Bispecific scFv immunofusion (BIf)
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
CA2887047A1 (en) 2012-10-05 2014-04-10 Cornell University Androgen suppression, prostate-specific membrane antigen and the concept of conditionally enhanced vulnerability
DK2924052T3 (da) 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN105814082A (zh) 2013-09-26 2016-07-27 埃博灵克斯股份有限公司 双特异性纳米抗体
DK3105252T3 (da) 2014-02-12 2019-10-14 Michael Uhlin Bispecifikke antistoffer til anvendelse ved stamcelletransplantation
WO2016081518A2 (en) 2014-11-17 2016-05-26 Adicet Bio, Inc. Engineered gamma delta t-cells
CA2979219A1 (en) 2015-03-10 2016-09-15 Sorrento Therapeutics, Inc. Antibody therapeutics that bind psma
US11000603B2 (en) 2015-04-14 2021-05-11 Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. Multi-specific binding conjugate, related pharmaceutical compositions and use
CN104829730A (zh) 2015-04-14 2015-08-12 苏静 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用
US10844122B2 (en) 2015-05-06 2020-11-24 Janssen Biotech, Inc. Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof
PT3294768T (pt) 2015-05-13 2019-11-05 Ablynx Nv Polipétidos de recrutamento de células t com base na reatividade do tcr alfa/beta
EA201792573A1 (ru) 2015-05-21 2018-04-30 Харпун Терапьютикс, Инк. Триспецифические связанные белки и способы их применения
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
LT3353212T (lt) 2015-09-23 2021-12-27 Regeneron Pharmaceuticals, Inc. Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
WO2017122019A1 (en) 2016-01-12 2017-07-20 Crescendo Biologics Limited Immunoconjugates that bind prostate specific membrane antigen (psma)
EP3192810A1 (en) 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum Psma binding antibody and uses thereof
KR102466763B1 (ko) 2016-04-13 2022-11-11 오리맵스 리미티드 항- psma 항체 및 이의 용도
CN109195992A (zh) 2016-04-29 2019-01-11 本康生物制药（深圳）有限公司 多特异性结合偶联物、相关的药物组合物及应用
CA3032304A1 (en) 2016-07-29 2018-02-01 New York University Gamma delta t cells as a target for treatment of solid tumors
US20190225702A1 (en) 2016-10-14 2019-07-25 Harpoon Therapeutics, Inc. Innate immune cell trispecific binding proteins and methods of use
WO2018140831A2 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
TWI687227B (zh) 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
RU2020135920A (ru) 2018-04-05 2022-05-05 Новартис Аг Триспецифические связывающие молекулы против форм рака и пути их применения
SG11202011633SA (en) 2018-05-24 2020-12-30 Janssen Biotech Inc Psma binding agents and uses thereof
SG11202012342WA (en) 2018-06-18 2021-01-28 Eureka Therapeutics Inc Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN113993893A (zh) 2019-02-01 2022-01-28 拉法医疗有限公司 新cd40结合抗体
AU2020226904B2 (en) 2019-02-21 2025-05-01 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
EP3965818A4 (en) 2019-05-08 2023-05-31 Janssen Biotech, Inc. MATERIALS AND METHODS FOR MODULATION OF T-CELL-MEDIATED IMMUNITY
CA3145523A1 (en) 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Therapeutic uses of anti-tcr delta variable 1 antibodies
US20220290101A1 (en) 2019-08-16 2022-09-15 GammaDelta Therapeutics Limited Ex vivo gamma delta t cell populations
EP3792283A1 (en) 2019-09-16 2021-03-17 Lava Therapeutics B.V. Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
KR20220147631A (ko) 2020-02-27 2022-11-03 얀센 바이오테크 인코포레이티드 면역 반응을 조절하기 위한 물질 및 방법
IL296358A (en) 2020-03-13 2022-11-01 Janssen Biotech Inc Materials and methods for modulating delta chain mediated immunity
WO2021231434A1 (en) 2020-05-12 2021-11-18 Harpoon Therapeutics, Inc. Psma targeting tritacs and methods of use
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
AR123935A1 (es) 2020-10-28 2023-01-25 Janssen Biotech Inc COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g
IL303045A (en) 2020-12-10 2023-07-01 Lava Therapeutics N V Antibodies that bind gamma-delta t cell receptors
CA3208069A1 (en) 2021-03-09 2022-09-15 Mary Ellen Molloy Combination therapy with immune cell engaging proteins and immunomodulators

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513521A (ja) * 2014-04-10 2017-06-01 シュティヒティング・フェーウーエムセー ヒトＶγ９Ｖδ２ Ｔ細胞受容体と結合する免疫グロブリン
WO2018098354A1 (en) * 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
JP2019535763A (ja) * 2016-11-23 2019-12-12 ハープーン セラピューティクス，インク． 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
JP2018188437A (ja) * 2017-05-05 2018-11-29 アムジエン・インコーポレーテツド 改善された貯蔵及び投与のための、二重特異性抗体構築物を含む医薬組成物
WO2019055841A1 (en) * 2017-09-14 2019-03-21 Denali Therapeutics Inc. ANTI-TREM2 ANTIBODIES AND METHODS OF USE
WO2019246514A1 (en) * 2018-06-21 2019-12-26 Regeneron Pharmaceuticals, Inc. Bispecific anti-psma x anti-cd28 antibodies and uses thereof
WO2020060406A1 (en) * 2018-09-19 2020-03-26 Lava Therapeutics B.V. Novel bispecific antibodies for use in the treatment of hematological malignancies
WO2020060405A1 (en) * 2018-09-19 2020-03-26 Lava Therapeutics B.V. Dual acting cd1d immunoglobulin
US20200190193A1 (en) * 2018-10-11 2020-06-18 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RENEE C. G. DE BRUIN, ET AL.: "A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity", ONCOIMMUNOLOGY, vol. 7(1), JPN7025002656, 2018, pages 1375641, ISSN: 0005619541 *

Also Published As

Publication number Publication date
KR20230042035A (ko) 2023-03-27
WO2022008646A1 (en) 2022-01-13
CN116323667A (zh) 2023-06-23
US20240317888A1 (en) 2024-09-26
AU2021305396A1 (en) 2023-02-09
IL299748A (en) 2023-03-01
EP4178981A1 (en) 2023-05-17
MX2023000448A (es) 2023-04-20
BR112023000269A2 (pt) 2023-03-28
US20230272110A1 (en) 2023-08-31
US12428493B2 (en) 2025-09-30
CA3188601A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
TWI830761B (zh) 針對cldn18.2和cd3之抗體構建體
JP7360440B2 (ja) Ｐｄ－ｌ１及びｃｄ１３７に結合する抗体分子
US12428493B2 (en) Antibodies that bind PSMA and gamma-delta T cell receptors
JP7369127B2 (ja) Ｔｉｇｉｔに対する単一ドメイン抗体及びその変異体
JP7425604B2 (ja) 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用
EP3224275B1 (en) Antigen binding molecules comprising a tnf family ligand trimer
JP7447208B2 (ja) 抗体
KR20220050971A (ko) 신규 항-cd39 항체
KR20190121816A (ko) 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
TW202128757A (zh) 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
JP2024501403A (ja) ガンマ－デルタｔ細胞受容体に結合する抗体
CA3208781A1 (en) Multispecific antibodies having specificity for ror1 and cd3
TW202413419A (zh) 與ｎｋｐ４６和ｂｃｍａ變體結合之具有ｆｃ工程化的自然殺手（ｎｋ）細胞接合物
JP2021525537A (ja) 三量体ポリペプチド複合体およびその使用
JP2023547662A (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
KR20220144821A (ko) Cd137 결합 분자 및 그것의 용도
JP2025524347A (ja) ガンマデルタｔ細胞受容体に結合するバリアント抗体
CN114539420B (zh) 抗b7-h3单克隆抗体、抗b7-h3×cd3双特异性抗体、制备方法及其应用
JP2021523688A (ja) 抗ｃｄ２７抗体およびその使用
EA048596B1 (ru) Антитела, которые связывают psma и гамма-дельта рецепторы т-клеток
JP2025525291A (ja) ガンマ－デルタｔ細胞受容体に結合する抗体を含む組成物
KR20250171367A (ko) Steap2 지향성 t 세포 결합제 및 이의 조성물
KR20250093362A (ko) TRAIL 또는 FasL에 특이적으로 결합하는 항체 조합 및 이중특이 항체
TW202544034A (zh) 結合至ｃｄ２８及ｎｅｃｔｉｎ－４之雙特異性抗體

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240708

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250917

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260127